Initiated four years ago, the Future project led by the German pharmaceutical group Adragos Pharma became a concrete reality on November 7 with the inauguration, in Livron (Drôme), of a new ampoule filling line for solutions injectables such as painkillers, anticoagulants or anti-inflammatories.
«This fourth line will allow us to produce ampoules with a capacity of 1 to 10 ml, which until now we were not able to offer to the forty clients we have in our portfoliorejoices Gaël Le Saux, director of the site whose bulb production capacity will increase by 40% and reach 170 million units per year. This new equipment will help ensure the sustainability of the site in an environment subject to increasing technical, regulatory and financial constraints.»
13 million euros of investment in two years
Two years of work and nearly 13 million euros (12.8 to be precise) were necessary to adapt the site, the origins of which date back to 1918 when the Rhône-Poulenc group decided to set up a pharmaceutical activity in former mills. disused before shedding them in the early 2000s. This investment, which benefited from a subsidy of 1.4 million euros as part of the France recovery plan, should generate the creation of around forty jobs which will be added to the existing 220. It is also intended to consolidate Adragos Pharma's position in its sector of activity and to perpetuate its positions in Germany, Norway, Greece and Japan.
Owned by a pension fund based in Northern Europe (FSN Capital Partners), the young group, whose head office is based in Bavaria, in Munich, has set itself the objective of joining the Top 15 by 2026. global pharmaceutical subcontractors.
